The Pharma Letter1d
Amgen’s MariTide falls short of analyst expectations in obesity
The Californian company earlier announced positive data at 52 weeks in a double-blind, dose-ranging Phase II study with ...
Daily3d
Eli Lilly Collaborates with Laekna to Develop Obesity Drug Targeting Muscle Preservation and Weight Loss
Bengaluru: Eli Lilly and Hong Kong-listed Laekna will collaborate to develop an experimental obesity drug that aims to help ...
The Pharma Letter6d
Lilly and Laekna team up on novel obesity drugs
Eli Lilly has partnered with Laekna to advance LAE102, an antibody targeting the ActRIIA receptor, for obesity and muscle ...
BioSpace6d
Lilly Partners With Chinese Biotech to Advance Muscle-Sparing Obesity Treatment
Lilly will provide the funding and expertise to advance Laekna’s LAE102, a first-in-class monoclonal antibody targeting the ...
Laekna, Inc. Announces Share Placement to Raise HK$230 Million
Laekna, Inc. (HK:2105) has released an update.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top Wall Street ...
阿思達克財經網7d
LAEKNA-B Last Slumps 7%+ after Announcing Shr Placing on 48% Rally Ytd
LAEKNA-B (02105.HK) -0.580 (-3.737%) announced a share placing immediately after a 48% share surge yesterday (20th). Today ...
阿思達克財經網7d
LAEKNA-B Places Shrs at 15%+ Discount to Raise $230M Net Proceeds
LAEKNA-B (02105.HK) -0.260 (-1.675%) announced that it intends to place a total of 17.636 million shares of the company, ...
China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug
Eli Lilly and Hong Kong-listed Laekna will collaborate to develop an experimental obesity drug that aims to help patients ...
Eli Lilly in pact with Chinese biotech for novel weight loss therapy
Eli Lilly (LLY) partners with Laekna Therapeutics to develop an obesity therapy that avoids muscle loss. Read more here.
Business Wire7d
Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obe…
Laekna, Inc. (2105.HK) (“Laekna”), a global biotech company focused on novel drug development for metabolic and cancer ...
Laekna Partners with Eli Lilly on Obesity Drug Development
Laekna, Inc. (HK:2105) has released an update.Don't Miss out on Research Tools:Discover the latest stocks recommended by top Wall Street ...
Yahoo Finance15d
Laekna, Inc. (2105.HK)
Laekna, Inc. (2105.HK), a science-driven, clinical-stage biotechnology company, announced that the company has received approval from the U.S. Food and Drugs Administration for the protocol of the ...